Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Older hospitalized adults with both magnesium and calcium deficiencies exhibit significantly lower cognitive function, highlighting the need for nutrient monitoring in aging populations.

Considering taking supplements to treat hypomagnesemia? Below is a list of common natural remedies used to treat or reduce the symptoms of hypomagnesemia. Follow the links to read common uses ...

Healthcare specialists said that magnesium is essential for those diagnosed with low magnesium levels (hypomagnesemia) or for ...

Sarepta has stopped developing SRP-5051, its exon 51-skipping therapy for Duchenne MD, due to long-term safety concerns and ...

In many cases, magnesium deficit in your body may go undiagnosed since the obvious signs commonly do not appear until your levels become severely low. Also known as hypomagnesemia, the lack of ...

Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem. The safety signal deprived Sarepta of a near-term shot at accelerated ...

SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations amenable to exon 51 skipping. With this ...

There were also no oligonucleotide class related safety events. As a reminder, WVE-N531 does not leverage muscle delivery ...

The most common adverse reactions (≥15%) in patients treated with KEBILIDI were dyskinesia (77%), pyrexia (38%), hypotension (31%), anemia (31%), salivary hypersecretion (23%), hypokalemia (23%), ...